Overview

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Status:
Completed
Trial end date:
1993-02-01
Target enrollment:
Participant gender:
Summary
The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Losartan